- Supported exchanges /
- NASDAQ /
- NRSNW.NASDAQ
NeuroSense Therapeutics Ltd. Warrant (NRSNW NASDAQ) stock market data APIs
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
NeuroSense Therapeutics Ltd. Warrant Financial Data Overview
| - | |
| 0.073-0.65 | |
| 0 | |
| 0 | |
| 0 | |
| -0.2695 | |
| 1.499 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
NeuroSense Therapeutics Ltd. Warrant Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -12 028 750
- Earnings Per Share -0.935
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get NeuroSense Therapeutics Ltd. Warrant Earnings via APIs
- Latest Release 2021-06-30
- EPS/Forecast 0
Get NeuroSense Therapeutics Ltd. Warrant End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
